FIGURE

Fig. 1

ID

ZDB-FIG-210119-11

Publication

El-Sahli et al., 2021 - A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature

Other Figures

All Figure Page

Back to All Figure Page

Fig. 1

Combination of verteporfin-NP, paclitaxel-NP, and/or combretastatin-NP suppressed both bulk tumor cells and cancer stem cells.

A The viability of TNBC MDA-MB-231 cells was determined by MTT assay after 120-hr treatment with E-NP (empty-nanoparticle), P-NP (paclitaxel-NP, 5 nM), V-NP (verteporfin-NP, 250 nM), C-NP (combretastatin-NP, 5 nM), or different combinations. B Tumorsphere (TS) formation, an in vitro assay indicating cancer stem cells (CSCs) after different treatments with drug-NPs. MDA-MB-231 cells overexpressing E-cadherin were grown in low attachment and serum-free conditions, and treated for 120 hrs as described in A, followed by MTT viability assay. C Representative photographs of TS shown in B. Data represent means ± SD, *P < 0.05, **P < 0.01, ****P < 0.001.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cell Death Dis.